Clin2
NCT05776524Possibly a fitRecruiting

Radiofrequency heat treatment for pancreas cancer spread to other organs

Pancreatic CancerMetastatic Adenocarcinoma

Treatments studied

Part of Cancer, Digestive system, Hormones & metabolism clinical trials.

This Phase 2 trial tests whether a device that delivers carefully timed “radiofrequency heat” through the body can slow or control metastatic (spread) pancreatic cancer. You may qualify if you have newly diagnosed metastatic pancreatic cancer and can meet safety and blood-test requirements.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
46 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have newly diagnosed metastatic pancreatic cancer proven by biopsy (or your doctor can use biopsy results from the original pancreatic mass, with a consistent picture).
  • Your scans show at least one measurable tumor in the chest, abdomen, or pelvis.
  • You must be 18 or older and able to do daily activities fairly well (ECOG performance status 0–1).
  • Your blood and organ tests must be within allowed ranges, or your team can use blood/platelet transfusions before starting.
  • You must use 2 reliable birth-control methods if you could become pregnant (or if you have a partner who could become pregnant) during treatment and for 6 months after.
  • You must be able to sign the informed consent and follow study visit/treatment schedules.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07126158Recruiting· Phase 2
Radiation plus targeted drugs for advanced pancreatic cancer

This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.

St Louis, Missouri
NCT04543071Recruiting· Phase 2
Second-line-like immunotherapy and chemo for metastatic pancreatic cancer

This Phase 2 trial studies a combination of immunotherapy, a blood-vessel/immune signal blocker, and chemotherapy for people with metastatic pancreatic adenocarcinoma. It may help shrink tumors and improve control of the disease.

New York, New York
NCT06026943Recruiting
Alpha radiation therapy for locally advanced pancreatic cancer

This trial tests a new treatment that uses tiny alpha radiation sources placed directly into the tumor to destroy cancer cells. It is for people with pancreatic cancer that has not spread but cannot be removed surgically, and who have already tried at least one type of chemotherapy or cannot take more chemo.

Verona
NCT06479239Recruiting· Phase 1/Phase 2
Immune cell therapy for advanced pancreatic cancer

This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.

Charlottesville, Virginia
NCT06576115Recruiting· Phase 2
Combination therapy with device for metastatic pancreatic cancer

This trial tests whether adding a non-invasive device that uses low-level radio waves to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with pancreatic cancer that has spread to other parts of the body.

Clarkston, Michigan
NCT05624918Recruiting· Phase 2
Testing a tumor-treatment device plus chemotherapy for pancreatic cancer

This trial studies NovoTTF-200T(P), a portable treatment device, combined with standard chemotherapy (gemcitabine and nab-paclitaxel) for people with resectable pancreatic adenocarcinoma. It aims to improve treatment results by trying this combination before surgery.

Columbus, Ohio

Hear when a new Pancreatic cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.